Complementation in Cells Cotransfected with a Mixture of Wild-Type and Mutant Human Immunodeficiency Virus (HIV) Influences the Replication Capacities and Phenotypes of Mutant Variants in a Single-Cycle HIV Resistance Assay
Open Access
- 1 September 2004
- journal article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 42 (9) , 4169-4174
- https://doi.org/10.1128/jcm.42.9.4169-4174.2004
Abstract
The impact of cotransfection of mixtures of mutant and wild type (WT) virus on the observed phenotype and replication capacity (RC) in a single-cycle human immunodeficiency virus (HIV) phenotypic assay has been investigated by cotransfecting mutant HIV clones expressing the firefly luciferase expression gene with a WT clone expressing Renilla luciferase. Four mutant constructs with different genotypes displayed 50 ) of lopinavir against seven mutant clones decreased by up to 97% after incremental cotransfection of 9 to 50% of the WT clone. The enhancement of RC and decrease in IC 50 for mutant variants following cotransfection with the WT variant appear to be due to complementation rather than genetic recombination. These findings suggest that the RC and susceptibility of plasma isolates from patients who are off therapy or not adherent to treatment, in which WT virus may expand to significant levels, should be interpreted with caution.Keywords
This publication has 31 references indexed in Scilit:
- Processivity and drug-dependence of HIV-1 proteaseAIDS, 2003
- Changes in Human Immunodeficiency Virus Type 1 Gag at Positions L449 and P453 Are Linked to I50V Protease Mutants In Vivo and Cause Reduction of Sensitivity to Amprenavir and Improved Viral Fitness In VitroJournal of Virology, 2002
- Evolution of Human Immunodeficiency Virus Type 1 Populations after Resumption of Therapy following Treatment Interruption and Shift in Resistance GenotypeThe Journal of Infectious Diseases, 2002
- Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug ResistanceClinical Microbiology Reviews, 2002
- Changes in Human Immunodeficiency Virus Type 1 Populations after Treatment Interruption in Patients Failing Antiretroviral TherapyJournal of Virology, 2001
- Clinical Use of Genotypic and Phenotypic Drug Resistance Testing to Monitor Antiretroviral ChemotherapyClinical Infectious Diseases, 2001
- Phenotypic Drug Susceptibility Testing Predicts Long‐Term Virologic Suppression Better than Treatment History in Patients with Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 2001
- Evolution of Lamivudine Resistance in Human Immunodeficiency Virus Type 1-Infected Individuals: the Relative Roles of Drift and SelectionJournal of Virology, 2000
- Drug resistance mutations can affect dimer stability of HIV-1 protease at neutral pHProtein Science, 1999
- Modulation of the affinity of aspartic proteases by the mutated residues in active site modelsFEBS Letters, 1990